AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Senseonics, Ascensia Diabetes Care Sign MoU for Eversense 365 CGM Transition
ByAinvest
Thursday, Sep 4, 2025 6:06 am ET1min read
Senseonics Holdings, a medical technology company, has signed a Memorandum of Understanding with Ascensia Diabetes Care to take over commercialization and distribution of Eversense 365 CGM. The transition will occur from Ascensia Diabetes Care to Senseonics, and Brian Hansen will be appointed Chief Commercial Officer. Senseonics has also expanded its non-dilutive debt facility up to $100 million with Hercules Capital to fund the commercial organization. A conference call is scheduled for September 4, 2025, at 8:00 A.M. Eastern Time.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet